Cord Dohrmann
Chief Tech/Sci/R&D Officer presso EVOTEC SE
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Attualmente, Cord E. Dohrmann ricopre la posizione di Chief Scientific Officer presso Evotec SE e Co-Managing Director presso Evotec International GmbH (una filiale di Evotec SE). È anche nel consiglio di amministrazione di Eternygen GmbH e FSHD Unlimited Cooperatie Ua. In precedenza è stato amministratore delegato di DeveloGen AG, direttore di The General Hospital Corp., direttore della Eberhard Karls Universitt Tbingen e direttore della Duke University. Il Dr. Dohrmann si è laureato al Max-Planck-Institute for Molecular Genetics, si è laureato alla Eberhard Karls Universitt Tbingen e ha conseguito il dottorato alla Harvard Medical School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
EVOTEC SE
0.11% | 31/12/2022 | 188 926 ( 0.11% ) | 3 M $ | 31/03/2024 |
Posizioni attive di Cord Dohrmann
Società | Posizione | Inizio |
---|---|---|
EVOTEC SE | Chief Tech/Sci/R&D Officer | 01/09/2010 |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Director/Board Member | - |
FSHD Unlimited Cooperatie Ua
FSHD Unlimited Cooperatie Ua Pharmaceuticals: MajorHealth Technology FSHD Unlimited Cooperatie Ua is a Dutch pharmaceutical company that specializes in facioscapulohumeral dystrophy. The private company is based in Leiden, the Netherlands and has subsidiaries in the Netherlands. The company was founded by Cornelis van der Graaf. | Director/Board Member | 01/06/2017 |
Evotec International GmbH
Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | Chief Executive Officer | - |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | Director/Board Member | - |
Facio Therapies | Director/Board Member | - |
German Council of Science & Humanities | Corporate Officer/Principal | - |
Precedenti posizioni note di Cord Dohrmann
Società | Posizione | Fine |
---|---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Chief Executive Officer | 25/01/2012 |
Eberhard Karls Universität Tübingen | Corporate Officer/Principal | - |
░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░ ░░░░░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Cord Dohrmann
Eberhard Karls Universität Tübingen | Undergraduate Degree |
Max-Planck-Institute for Molecular Genetics | Graduate Degree |
Harvard Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
EVOTEC SE | Health Technology |
Aziende private | 8 |
---|---|
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Evotec International GmbH
Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | Commercial Services |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
Facio Therapies | |
Breakpoint Therapeutics GmbH
Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | Health Technology |
German Council of Science & Humanities | |
FSHD Unlimited Cooperatie Ua
FSHD Unlimited Cooperatie Ua Pharmaceuticals: MajorHealth Technology FSHD Unlimited Cooperatie Ua is a Dutch pharmaceutical company that specializes in facioscapulohumeral dystrophy. The private company is based in Leiden, the Netherlands and has subsidiaries in the Netherlands. The company was founded by Cornelis van der Graaf. | Health Technology |
- Borsa valori
- Insiders
- Cord Dohrmann